TAUG — Tauriga Sciences Income Statement
0.000.00%
Last trade - 00:00
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $0.44m
- $0.29m
2017 March 31st | R2018 March 31st | 2019 March 31st | C2020 March 31st | 2021 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.057 | 0.234 | 0.285 |
Cost of Revenue | |||||
Gross Profit | 0 | 0 | 0.02 | 0.054 | 0.123 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1.45 | -0.47 | 1.19 | 2.15 | 3.99 |
Operating Profit | -1.45 | 0.47 | -1.13 | -1.92 | -3.7 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -2.27 | 0.003 | -1.1 | -3.03 | -3.63 |
Net Income After Taxes | -2.27 | 0.003 | -1.1 | -3.03 | -3.63 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -2.27 | -0.036 | -1.1 | -3.03 | -3.63 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.27 | -0.307 | -1.1 | -3.03 | -3.63 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.124 | -0.078 | -0.019 | -0.039 | -0.017 |